2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
- Francis, J., Zvada, S. P., Denti, P., Hatherill, M., Charalambous, S., Mungofa, S., Dawson, R., Dorman, S., Gupte, N., Wiesner, L., Jindani, A., Harrison, T. S., Olagunju, A., Egan, D., Owen, A., & McIlleron, H. M. (2019). A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine. Antimicrobial Agents and Chemotherapy, 63(4). https://doi.org/10.1128/AAC.01964-18
- Egan, D., Olagunju, A., Gupte, N., Owen, A., Denti, P., Dawson, R., Hatherill, M., Dorman, S., Mungofa, S., Wiesner, L., Harrison, T. S., McIlleron, H. M., Zvada, S. P., Francis, J., Jindani, A., & Charalambous, S. (2019). Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis. Antimicrobial Agents and Chemotherapy, September 2018, 1–8. https://doi.org/10.1128/aac.01964-18
- Sekaggya-Wiltshire, C., Chirehwa, M., Musaazi, J., Von Braun, A., Buzibye, A., Muller, D., Gutteck, U., Motta, I., Calcagno, A., Fehr, J. S., Kambugu, A., Castelnuovo, B., Lamorde, M., & Denti, P. (2019). Low antituberculosis drug concentrations in HIV-tuberculosis-coinfected adults with low body weight: Is it time to update dosing guidelines? Antimicrobial Agents and Chemotherapy, 63(6). https://doi.org/10.1128/AAC.02174-18
- Garcia-Prats, A. J., Purchase, S. E., Osman, M., Draper, H. R., Simon Schaaf, H., Wiesner, L., Denti, P., & Hesseling, A. C. (2019). Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure. Antimicrobial Agents and Chemotherapy, 63(4). https://doi.org/10.1128/AAC.01865-18
- Wasserman, S., Denti, P., Brust, J. C. M., Abdelwahab, M., Hlungulu, S., Wiesner, L., Norman, J., Sirgel, F. A., Warren, R. M., Esmail, A., Dheda, K., Gandhi, N. R., Meintjes, G., & Maartens, G. (2019). Linezolid pharmacokinetics in South African patients with drug-resistant tuberculosis and a high prevalence of HIV coinfection. Antimicrobial Agents and Chemotherapy, 63(3). https://doi.org/10.1128/AAC.02164-18
- Naidoo, A., Chirehwa, M., Ramsuran, V., McIlleron, H., Naidoo, K., Yende-Zuma, N., Singh, R., Ncgapu, S., Adamson, J., Govender, K., Denti, P., & Padayatchi, N. (2019). Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. Pharmacogenomics, 20(4), 224–240. https://doi.org/10.2217/pgs-2018-0166
- Rabie MMed Paed, H., Denti, P., McIlleron, H., Rabie, H., Denti, P., Lee, J., Masango, M., Coovadia, A., Pillay, S., Liberty, A., Simon, F., McIlleron, H., Cotton, M. F., & Lallemant, M. (2019). Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. Lancet HIV, 6, 32–42. https://doi.org/10.1016/S2352-3018(18)30293-5